Goldman also slashes its one-year price target by nearly two-thirds on expectations that Nektar's in-the-works cancer treatment won't generate revenue anytime soon.
Three top executives -- CEO Paula Soteropoulos as well as the president and the COO -- stepped down.
Merck says it's the first combination treatment to receive simultaneous review decisions in the U.S., Australia and Canada.
BioDelivery Sciences International, Chiasma Inc. and TherapeticsMD all feature promising treatments.
Acadia Pharmaceuticals rockets higher after it announces it has ended a phase 3 trial of its dementia-related psychosis treatment, pimavanserin, on better-than-expected results.
Shares of drugmaker Mallinckrodt plunge on a report the company is considering filing for bankruptcy as a way of dealing with its opioid-related legal liabilities.
Rova-T failed to show a survival benefit for patients when compared with a placebo.
Amgen is finally making an expected splash out of its cash pile, but questions are abounding about the cost paid for Celgene's Otezla.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.